Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression

Figure 2

SEPT9 is amplified and overexpressed during breast tumorigenesis. (A) SEPT9 mRNA levels quantified in primary breast tumors (light gray circles), tumor-free adjacent tissues (dark gray) and normal breast tissues from reduction mammoplasty (black circles). (B) Quantification of SEPT9 protein expression in breast primary tumors (light gray circles), tumor-free adjacent tissues (dark gray circles) and normal breast tissues from reduction mammoplasty (black circles). (C) Quantification of Sept9 gene copy number in normal mammary tissues and in primary mammary adenocarcinomas isolated from the PyMT mouse model at various stages of tumorigenesis (MG, normal mammary gland; 6 weeks premalignant hyperplasia, 8.9 weeks adenoma, and 14 and 20 weeks early and late carcinomas, respectively). Legend indicates copy number categories. (D) Sept9 mRNA levels in PyMT murine normal (black circles) and primary adenocarcinoma (light gray circles) mammary tissues. (E) Western blot depicting the pattern of Sept9 isoform (top panel) and α-tubulin (bottom panel) expression in normal mammary tissues and in primary mammary adenocarcinomas isolated from the PyMT mouse model at various stages of tumorigenesis. Values at the bottom indicate Sept9 expression levels normalized to α-tubulin. Only the bands between 37 and 75 kDa were used for quantification. T47D human breast cancer cell line in lane 9 was used as a reference to aid in isoform identification. (F) Left and center panels: immunohistofluorescence labeling of SEPT9 (red) and α-tubulin (green) in normal breast and adenocarcinoma tissues. White arrowheads indicate SEPT9 nuclear staining. Right panel: Colocalization of SEPT9 (red) and nucleolin (green) in normal breast tissues.

Back to article page